

## Review Article

# Ocular Distribution of the Renin-Angiotensin-Aldosterone System in the Context of the SARS-CoV-2 Pandemic

Ali Abid <sup>1</sup>, Muhammad Azaan Khan,<sup>1</sup> Brendon Lee,<sup>1</sup> Andrew White <sup>1</sup>, Nicole Carnt,<sup>1,2</sup> Sana Arshad,<sup>2</sup> and Chameen Samarawickrama <sup>1,2</sup>

<sup>1</sup>University of New South Wales, Australia

<sup>2</sup>University of Sydney, Australia

Correspondence should be addressed to Chameen Samarawickrama; [chameen.sams@sydney.edu.au](mailto:chameen.sams@sydney.edu.au)

Received 26 March 2021; Accepted 22 December 2021; Published 3 February 2022

Academic Editor: Vijaya Anand

Copyright © 2022 Ali Abid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The COVID-19 pandemic has resulted in an unprecedented impact on global health, economy, and way of life. SARS-CoV-2, the virus responsible for the disease, utilizes the ACE2 receptor found on host cells to mediate entry, replication, and infection. Numerous studies have elucidated the presence of many components of the renin-angiotensin-aldosterone system (RAAS) in the eye, including the ACE2 receptor. Considering this, and the anatomical vulnerability that the exposed ocular surface offers with its interconnectedness to the respiratory system, there is a theoretical risk of pathogen entry from the ocular route as well as the development of COVID-19-associated eye disease. Despite this, the actual epidemiological data demonstrates low ocular symptoms, possibly due to differing ACE2 receptor expression across age, ethnicity, and sex coupled with the protective properties of tears. We summarize the current literature on ocular RAAS with specific focus on the ACE2 receptor and its interplay with the SARS-CoV-2 virus.

## 1. Methods

A search of PubMed, MEDLINE, and Embase databases were conducted between June 2020 and December 2021 with the following search terms: coronavirus infections, SARS-CoV-2, coronavirus, betacoronavirus, COVID-19, nCoV, renin-angiotensin system, renin-angiotensin-aldosterone system, RAAS, RAS, angiotensin-converting enzyme 2, ACE2, eye, eyelids, ocular, lacrimal, and conjunctiva. Two independent reviewers (AA and MK) collated relevant articles by screening titles and abstracts with the results compared and combined. The search was limited to English papers, but with no restriction on publication year. Furthermore, citation chaining was utilized to ensure that no landmark studies were missed. A total of 176 references were studied and analyzed (Figure 1).

## 2. Coronavirus and the Ocular Renin-Angiotensin-Aldosterone System

*2.1. Coronavirus.* Coronaviruses belong to the *Coronaviridae* family, which are a large group of single-stranded RNA viruses that cause disease in animals and humans. They can be further classified into four genera: *Alphacoronavirus* and *Betacoronavirus* which infect mammals while *Gamma-coronavirus* and *Deltacoronavirus* primarily infect birds and pigs [1]. There are seven known coronaviruses which infect humans, four of which cause mild respiratory symptoms. The other three are responsible for extensive morbidity and mortality as a result of global pandemics: Severe Acute Respiratory Syndrome (SARS) of 2002-03, Middle Eastern Respiratory Syndrome (MERS), and the recent Coronavirus Disease of 2019 (COVID-19) [1].




FIGURE 1: Flow chart depicting the methods used to curate this literature review.

COVID-19 was declared a pandemic by the World Health Organization on the 11<sup>th</sup> of March 2020. As of 10<sup>th</sup> December 2021, over 267 million people have been infected and over 5 million deaths have been attributed to the virus [2]. With its global spread, a concentrated effort has gone into research of the responsible virus. SARS-CoV-2 is a spherical, enveloped virus that comprises of four structural proteins: surface, membrane, envelope, and nucleocapsid proteins. The surface protein is fundamental for the pathogenicity of the virus as it is involved in host cell binding. Angiotensin-converting enzyme 2 (ACE2) is the human surface receptor that is utilized by SARS-CoV-2 to facilitate infection [3].

**2.2. Mechanisms of Infection in SARS-CoV-2.** The initial pre-*se* of COVID-19 was released in late December of 2019 by an ophthalmologist, Dr. Li Wenliang. He warned about the possibility of a new SARS-like virus [4] after seeing patients

with SARS-like symptoms at Wuhan Central Hospital. He later described becoming infected by SARS-CoV-2 after managing a patient with glaucoma in January 2020. Several COVID-19 cases displaying ocular symptoms have been recorded [5] instructing attentive observers about the possible ocular entry point and tropism that SARS-CoV-2 displays, facilitating respiratory but also intrinsic eye disease as well. The molecular and anatomical mechanisms of SARS-CoV-2 infection will be reviewed in the following sections.

**2.2.1. Receptor Mechanisms of Infection.** The SARS-CoV-2 virus, like other betacoronaviruses, utilizes the ACE2 receptor on the surface of host cells for invasion and cellular entry (Figure 2). This has been demonstrated in virus infectivity studies using HeLa cells, where cells not expressing ACE2 were not infected by SARS-CoV-2, while cells that did express ACE2 were infected [6]. The receptor-binding




FIGURE 2: SARS-CoV-2 utilizing the ACE2 receptor located on human cells to mediate entry and replication.

domain of the spike protein located on the viral surface mediates binding to the ACE2 receptor. This occurs after priming of the spike protein by transmembrane protease, serine 2 (TMPRSS2). In fact, the binding of SARS-CoV-2 to ACE2 appears to have greater affinity compared to SARS-CoV which may contribute to the higher reproductive number ( $R_0$ ) of SARS-CoV-2, that is, more susceptible individuals are being infected from a single confirmed COVID-19 patient [7, 8].

**2.2.2. Ocular ACE2 and RAAS Components.** The ACE2 receptor, a type 1 membrane-bound glycoprotein, is a crucial pivot between the classical and protective RAAS axes. It is highly expressed in vascular tissue, where it downregulates the RAAS by degrading angiotensin II (Ang II) to Ang (1–7). This has been identified to a lesser extent in numerous other organs as well. The presence of ocular ACE2 (Table 1) has been confirmed in low concentrations in the conjunctiva and cornea (especially their superficial layers [9]), the limbus, aqueous humour, and retina [10–13].

Since the discovery of renin-like activity in canine neurological tissue independent of renal renin in 1971, the local production and activity of RAAS constituents have been detected in various tissues including the eye [14]. The main components of both axes have been found across all ocular tissues, as detailed in Table 1. However, the role of local RAAS on ocular diseases and its interplay with systemic RAAS remains unclear. Currently, ocular RAAS has been implicated in diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, cataract, uveitis, glaucoma, and more recently, SARS-CoV-2 [10].

**2.2.3. Anatomical Mechanism of Infection.** The eyes are anatomically located to provide a maximal field of view allowing for perception of the environment. However, there is an inherent vulnerability with its positioning and interconnectedness with the respiratory system, increasing susceptibility

to airborne viruses. Despite being small organs, they have considerable surface areas, with several studies estimating a total palpebral aperture area between 226 and 640 mm<sup>2</sup> [37, 38]. Additionally, the periorbital region also needs to be considered as it provides further area for virions to land and then migrate into the eye. This phenomenon is often witnessed when cosmetics applied around the eye drift to the eye's surface, possibly due to the action of Riolan's muscle [39]. Furthermore, the eyelids, which are responsible for keeping out foreign bodies from the eyes, may actually not be as protective to viral entry. Application of ointments on the eyelid skin, which is then transported to the eye, has been shown to be an efficient treatment modality for dry eye syndrome and this adds to the possibility of viral migration from eyelid skin to the eye. Overall, the cumulative area of the ocular surface, the eyelid skin, and the periorbital region approximately equates to 10,000 mm<sup>2</sup>, which is twice the area of the nares and mouth [39].

Not only would a large surface area contribute to viral eye infection but it has also been shown that the anatomical connection between the eyes and the respiratory system, via the nasolacrimal ducts (Figure 3), can facilitate pathogenic spread to the lungs and gastrointestinal system [40].

Furthermore, the conjunctiva forms part of the organised mucosal-associated lymphoid tissues (Figure 4) known as conjunctiva-associated lymphoid tissue [41]. The lymphoid follicles of the conjunctiva ensure detection and presentation of antigens and generate an immune response that drains into the nasal-associated lymphoid tissue [41] which is continuous with lung mucosa, highlighting the compelling relationship between the respiratory system and the ocular surface. Thus, the anatomical structure of the eyes and surrounding structures may contribute to ocular and systemic disease.

**2.3. Ocular Symptoms in COVID-19.** The primary ocular finding of COVID-19, although uncommon, has been described as mild conjunctivitis, similar to that caused by other viral aetiologies. There have been other features also reported including unilateral/bilateral conjunctival hyperaemia, chemosis, epiphora, and mild eyelid oedema [42]. However, numerous studies and case series are being published demonstrating that unlike the widespread respiratory disease that the COVID-19 pandemic is causing, the occurrence of ocular symptoms is limited [43–45]. Despite the aforementioned theoretical risk of infection due to the anatomy of the eye and its adnexa and presence of ACE2 receptors on the ocular surface, the epidemiological data indicates that there may be other factors which influence the acquisition of ocular disease, discussed in the following.

**2.3.1. ACE2 Receptor Density.** A consideration of SARS-CoV-2 infection is the location and density of ACE2 receptors. As described above, the portal of entry of the virus is through the ACE2 receptor, thus the inference can be made that the greater the number of ACE2 receptors, the increased susceptibility one has to viral entry and therefore infection. Examining the demographics of COVID-19 patients, there is a predominance of adult patients with only a minority of






FIGURE 3: Anatomy of the nasolacrimal duct depicting a conduit between the eyes and the nose, and therefore the respiratory system.




FIGURE 4: Mucosal-associated lymphoid tissue (MALT) are organised lymphoid structures including the conjunctiva (CALT), bronchus (BALT), nose (NALT), gut (GALT), and vulvovaginal (VALT).

patients being young children, with any affected children showing less severe disease. A study investigating the levels of *ACE2* gene expression in the nasal epithelia of individuals ages 4-60 years revealed that there exists an age-dependent expression of the *ACE2* gene with younger children (4-9 years) having the lowest levels [46].

Moreover, it has been revealed that the concentration of *ACE2* receptors in the conjunctival epithelial cells is less than that in the lungs [47], a possible explanation for the lower occurrence of ocular symptoms.

**2.3.2. Protective Properties of Tears.** Tears have an important immunological role as they contain antimicrobial agents including lactoferrin and immunoglobulin A, which protect

the eyes from infection by neutralizing pathogens. In addition, the flow of tears across the eye's surface into the nasolacrimal duct may serve as a mechanism of directing the SARS-CoV-2 virus away from the eyes and into the nose and lungs, possibly contributing to the low ocular and high respiratory symptoms [44]. This phenomenon was also confirmed in an animal study of cynomolgus macaque monkeys inoculated with SARS-CoV-2 via different potential routes of infection (conjunctival, tracheal, and gastric) [48]. The results revealed that the monkeys inoculated via the conjunctiva had a detectable load in the conjunctiva for the first day after inoculation, with subsequent detection in the nasal mucosa from days one to seven [48]. Therefore, the flow of tears from the eyes to the nose may be a possible route of respiratory infection, and an inherent protection mechanism against ocular infection.

**2.3.3. SARS-CoV-2 and the Inflammatory Response.** An important consideration is the immune response to a virus and the degree of inflammation that is initiated to eliminate it. A study analyzed the innate host response to SARS-CoV-2 and compared it to other viruses including the MERS-CoV virus, the H1N1 virus causing the 2009 influenza pandemic, and the H5N1 virus causing the highly pathogenic avian influenza. It found that SARS-CoV-2 resulted in fewer pro-inflammatory cytokine production in *in vitro* cultures of human alveolar epithelial cells than the aforementioned viruses [49].

Additionally, a recent systematic review demonstrated that SARS-CoV-2 causes a unique cytokine response when compared with other respiratory viruses, where the often-implicated cytokines (IL-2, IL-10, IL-4, or IL-5.) are not a driving feature against the virus [50].

It is possible that these characteristics of the virus may account for low ocular symptoms, but this is yet to be proven with targeted studies on conjunctival and corneal cell samples.

**2.4. Downregulation of *ACE2* Expression/SARS-CoV-2's Interaction with the RAAS.** As mentioned, the *ACE2* receptor converts Ang II into angiotensin (1-7), a peptide that has the opposite functioning of Ang II, exerting a counterbalancing effect through vasodilation and antiproliferation. Indeed, there is a growing body of evidence demonstrating the protective effects it has on many pathologies such as hypertension and diabetic retinopathy [51-53].

The utilization of the *ACE2* receptor by SARS-CoV-2 is not innocuous, and there is evidence that its interaction with this receptor may have a crucial effect on the RAAS. A study examined the pathogenesis of SARS-CoV and the development of acute lung injury through the virus' interaction with the *ACE2* receptor [54]. It revealed that the virus downregulated the *ACE2* receptor and this exaggerated lung failure due to the disturbance caused to the RAAS [55]. It was hypothesized that the decreased expression of the *ACE2* receptors results in a local accumulation of Ang II which exerts its proinflammatory effects, augmenting lung injury. This finding may be translated to the SARS-CoV-2 virus since it utilizes the same receptor for cellular entry. There

is a need for further research to determine its pathogenesis, helping to elucidate possible treatment modalities. If this finding is true for the SARS-CoV-2, it could mean that patients suffering from COVID-19, displaying ocular symptoms, who also have comorbid eye disease such as diabetic retinopathy may experience a worsening of their eye disease as the protective axis of the RAAS is suppressed, albeit transiently while they have the infection. However, this is likely not an implication for the majority of ophthalmic patients given the low prevalence of ocular symptoms, likely due to the aforementioned protective mechanisms.

**2.5. Influence of Ethnicity, Age, and Sex on the Acquisition, Severity, and Morbidity of SARS-CoV-2.** Ethnicity, age, and gender have been increasingly recognised to have an impact on the acquisition, severity, and morbidity of SARS-CoV-2 due to the central importance of the ACE2 receptor in enabling COVID-19 [56–60].

Significant variation in incidence and severity of COVID-19 have been documented across various ethnic groups. The UK census results indicated, after controlling for demographic and socioeconomic factors, that Black males are 4.2 times more likely to die from a COVID-19-related death than White males and Black females are 4.3 times more likely to die than White females. Furthermore, Bangladeshi, Pakistani, Indian, and mixed ethnicities were also at a statistically significant higher risk of death than White ethnicity [61]. A systematic review demonstrated that Black, Asian, and minority ethnicity patients were at a higher risk of acquiring SARS-CoV-2 infection (with Black ethnicity being the highest), and preprint literature suggested that Black and Asian ethnicities were at an increased risk of hospitalisation, admission to intensive care units, and death [59].

A potential link between SARS-CoV-2 and ethnicity has been proposed, which relates to the genetic variations and expression of ACE2 levels [59]. The importance of genetic variations has been further confirmed in the COVID-19 Chinese Han population, with overexpression of *ACE2* [60] and lower AA genotype, and A allele frequencies of *CD86 rs1129055*<sup>9</sup> being linked to ARDS, and sepsis, respectively. A recent study on lung cells via single-cell RNA sequencing also found higher ACE2 pulmonary levels in Asian than White and African American donors [60]. Thus, the described polymorphisms and genetic variations in *ACE2* expression levels can likely affect the binding affinity and infection rate of SARS-CoV-2 to the human ACE2 protein [62] proffering an explanation to the differing epidemiological COVID-19 findings across ethnicities.

The severity of SARS-CoV-2 has been documented to be worse in males than females. A study examining the ACE2-expressing patterns found a higher cell ratio in males compared to females (1.66% vs. 0.41% of all cells,  $p = 0.07$ ) [60]. Additionally, the distribution of ACE2 was more prevalent in male donors than females (5 types of cells in male lung with this receptor vs. 2-4 types of cells in female lung cells) [60]. Epidemiology studies have demonstrated that males are slightly more affected but greatly skewed in terms of severe illness and fatality. An analysis conducted early in

2020 demonstrated that of the 44,672 confirmed patients, males represented 51.4% of the total patients but 63.8% of the deaths [56]. Patients older than 60 years tend to develop more severe COVID symptoms and critical complications from the disease [56].

**2.6. Potential Treatment Options Using the RAAS.** Currently, there are no treatment modalities which take advantage of SARS-CoV-2's dependence on the ACE2 receptor for host cell entry. Blocking this mode of entry may be a potential therapeutic advancement and may curtail disease propagation within society. It appears investigation of drugs with an anti-ACE2 mechanism of action is limited. For the treatment of SARS, N-(2-aminoethyl)-1-aziridine-ethanamine, a small peptide which inhibits the activity of ACE2 was developed, but there was concern about its narrow spectrum of activity and probable effects on the RAAS function [63]. Theoretically, blocking ACE2 may result in an increase in local Ang II levels leading to inflammation and fibrosis since the classical RAAS pathway is being favoured by restricting the alternative pathway to carry out its function since ACE2 is blocked. The proinflammatory and profibrotic characteristics of the classical pathway have been extensively studied and demonstrated in other disease states such as interstitial lung disease, liver fibrosis and portal hypertension, and myocardial fibrosis [64–66].

However, there have been no laboratory or clinical studies conducted to verify this concern. Thus, focused attention to the cultivation and development of drugs which block ACE2 receptors to limit SARS-CoV-2 entry but ensure host safety may be productive. This may then be used as both treatment and prophylaxis to prevent disease transmission from both respiratory and ocular routes.

As of December 10th, 2021, there are 137 vaccine candidates that are undergoing research and testing in human trials and 194 candidates in preclinical development [67], but none focus on the RAAS pathway in its mode of action. Numerous techniques have been utilized to develop vaccines that facilitate host immune response and confer secondary immunity, including mRNA and DNA technology, viral vectors (replicating and nonreplicating), inactivated viruses, live attenuated viruses, and protein subunit vaccines [68]. The main three vaccines currently available are the Pfizer/BioNTech vaccine, the Moderna vaccine, and the AstraZeneca/Oxford vaccine.

The Pfizer/BioNTech vaccine (BNT162b2) has the most emergency use approvals from countries including the UK, Canada, and the US and demonstrates a 95% efficacy in preventing COVID-19 [69]. It utilizes mRNA enclosed in a lipid carrier to stimulate the production of host memory B and T cells to the SARS-CoV-2 spike protein. In addition to reducing the number of subjects infected with COVID-19, it also reduces the severity of symptoms for those vaccinated. This vaccine needs to be kept at -70 degrees Celsius for long term storage, which poses its own unique challenges in the global setting [70].

The Moderna vaccine also utilizes mRNA contained within a phospholipid nanoparticle and has received emergency use authorisation in the US. Unlike the Pfizer/

BioNTech vaccine, the Moderna vaccine has more pragmatic storage conditions with the vaccine being able to be stored at 2-8 degrees Celsius for up to thirty days [71]. It has shown efficacious results in the phase III trial with 94.1% reduction in COVID-19 symptoms in those who received the vaccine [72].

The AstraZeneca/Oxford vaccine has a different method of priming host defences. It uses a chimpanzee adenovirus to insert DNA coding for the SARS-CoV-2 spike protein into host cells so that translational and transcriptional enzymes can convert these genetic instructions into the spike protein for display on MHC class I/II, generating memory B and T cells [73]. It has similar storage requirements to the Moderna vaccine (2-8 degrees Celsius) but has lower reported efficacy of 70% [74].

Despite these vaccines and the estimation that by the end of 2021 there will be billions of vaccine doses ready for administration worldwide [75], the current best practice for disease prevention still remains social distancing amongst community members and isolation of COVID-19 patients [76].

### 3. Conclusion

Despite the presence of ACE2 on various ocular structures, the incidence of COVID-19-associated eye disease remains low. This may be explained by the differing ACE2 receptor densities in the eyes as compared to the lungs coupled with the protective property of tears and the intrinsic host inflammatory response being milder and orchestrated by different cytokines targeted against SARS-CoV-2 as compared to other respiratory viruses. These suppositions need to be confirmed with studies on conjunctival and corneal cell samples.

### Abbreviations

ACE2:	Angiotensin-converting enzyme 2
Ang II:	Angiotensin II
COVID-19:	Coronavirus disease of 2019
MERS:	Middle Eastern Respiratory Syndrome
RAAS:	Renin-angiotensin-aldosterone system
RNA:	Ribonucleic acid
SARS:	Severe Acute Respiratory Syndrome
TMPRSS2:	Transmembrane protease, serine 2.

### Data Availability

The data supporting this review article are from previously reported studies and datasets, which have been cited.

### Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

### Acknowledgments

CS is funded by a National Health and Medical Research Council (NHMRC) Investigator Grant (APP1175949).

### References

- [1] M. Pal, G. Berhanu, and C. Desalegn, "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update," *Cureus*, vol. 12, pp. e7423–e7423, 2020.
- [2] World Health Organisation, *WHO coronavirus disease (COVID-19) dashboard*, 2021, <https://covid19.who.int/>.
- [3] W. Ni, X. Yang, D. Yang et al., "Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19," *Critical Care*, vol. 24, no. 1, p. 422, 2020.
- [4] A. Green, "Li Wenliang," *The Lancet*, vol. 395, p. 682, 2020.
- [5] P. Wu, F. Duan, and C. Luo, "Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China," *JAMA Ophthalmology*, vol. 138, pp. 575–578, 2020.
- [6] P. Zhou, X.-L. Yang, and X.-G. Wang, *Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin*, Cold Spring Harbor Laboratory, 2020.
- [7] M. D'Arienzo and A. Coniglio, "Assessment of the SARS-CoV-2 basic reproduction number, R(0), based on the early phase of COVID-19 outbreak in Italy," *Biosaf Health*, vol. 2, pp. 57–59, 2020.
- [8] N. Petrosillo, G. Viceconte, O. Ergonul, G. Ippolito, and E. Petersen, "COVID-19, SARS and MERS: are they closely related?," *Clinical Microbiology and Infection*, vol. 26, pp. 729–734, 2020.
- [9] L. Zhou, Z. Xu, and G. M. Castiglione, "ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection," *bioRxiv* 2020: 2020.2005.2009.086165.
- [10] R. Choudhary, M. S. Kapoor, A. Singh, and S. H. Bodakhe, "Therapeutic targets of renin-angiotensin system in ocular disorders," *Journal of Current Ophthalmology*, vol. 29, pp. 7–16, 2017.
- [11] R. S. Grajewski, A. C. Rokohl, M. Becker et al., "A missing link between SARS-CoV-2 and the eye?: ACE2 expression on the ocular surface," *Journal of Medical Virology*, vol. 93, 2021.
- [12] C.-B. C. Di Ma, V. Jhanji, C. Xu et al., "Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea," *Eye*, vol. 34, no. 7, pp. 1212–1219, 2020.
- [13] Y. Xiaolei and Z. Jinping, "Research progress on ocular surface  $\beta$  genus coronavirus receptors," *Chinese Journal of Experimental Ophthalmology*, vol. 38, pp. 254–256, 2020.
- [14] M. Holappa, H. Vapaatalo, and A. Vaajanen, "Many faces of renin-angiotensin system - focus on eye," *The Open Ophthalmology Journal*, vol. 11, pp. 122–142, 2017.
- [15] A. J. R. White, S. C. Cheruvu, M. Sarris et al., "Expression of classical components of the renin-angiotensin system in the human eye," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 16, no. 1, pp. 59–66, 2015.
- [16] I. H. Wallow, S. J. Sramek, and C. D. Bindley, "Ocular renin angiotensin: EM immunocytochemical localization of prorenin," *Current Eye Research*, vol. 12, no. 10, pp. 945–950, 1993.
- [17] S. J. Sramek, I. H. Wallow, and R. P. Day, "Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue," *Investigative ophthalmology & visual science*, vol. 29, no. 11, pp. 1749–1752, 1988.

- [18] A. H. Danser, M. A. van den Dorpel, and J. Deinum, "Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy," *The Journal of Clinical Endocrinology and Metabolism*, vol. 68, no. 1, pp. 160–167, 1989.
- [19] J. L. Berka, A. J. Stubbs, and D. Z. Wang, "Renin-containing Müller cells of the retina display endocrine features," *Investigative ophthalmology & visual science*, vol. 36, no. 7, pp. 1450–1458, 1995.
- [20] U. R. Chowdhury, B. J. Madden, M. C. Charlesworth, and M. P. Fautsch, "Proteome analysis of human aqueous humor," *Investigative ophthalmology & visual science*, vol. 51, pp. 4921–4931, 2010.
- [21] S. J. Sramek, I. H. Wallow, and D. A. Tewksbury, "An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen," *Investigative ophthalmology & visual science*, vol. 33, no. 5, pp. 1627–1632, 1992.
- [22] A. B. Cullinane, P. S. Leung, and J. Ortego, "Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium," *The British Journal of Ophthalmology*, vol. 86, pp. 676–683, 2002.
- [23] J. Wagner, A. H. Jan Danser, and F. H. Derkx, "Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system," *British Journal of Ophthalmology*, vol. 80, p. 159, 1996.
- [24] A. H. Danser, F. H. Derkx, and P. J. Admiraal, "Angiotensin levels in the eye," *Investigative ophthalmology & visual science*, vol. 35, no. 3, pp. 1008–1018, 1994.
- [25] E. Savaskan, K. U. Löffler, and F. Meier, "Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues," *Ophthalmic Research*, vol. 36, no. 6, pp. 312–320, 2004.
- [26] P. de Senanayake, J. Drazba, K. Shadrach et al., "Angiotensin II and its receptor subtypes in the human retina," *Investigative Ophthalmology & Visual Science*, vol. 48, no. 7, pp. 3301–3311, 2007.
- [27] A. Vaajanen, G. Kalesnykas, and H. Vapaatalo, "The expression of Mas-receptor of the renin-angiotensin system in the human eye," *Graefes's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie*, vol. 253, no. 7, pp. 1053–1059, 2015.
- [28] M. Holappa, J. Valjakka, and A. Vaajanen, "Angiotensin(1-7) and ACE2, "the hot spots" of renin-angiotensin system, detected in the human aqueous humor," *Open Ophthalmology Journal*, vol. 9, no. 1, pp. 28–32, 2015.
- [29] J. B. Vita, J. A. Anderson, and C. D. Hulem, "Angiotensin-converting enzyme activity in ocular fluids," *Investigative Ophthalmology & Visual Science*, vol. 2, 1981.
- [30] R. N. Weinreb, J. R. Polansky, and S. G. Kramer, "Acute effects of dexamethasone on intraocular pressure in glaucoma," *Investigative ophthalmology & visual science*, vol. 26, no. 2, pp. 170–175, 1985.
- [31] E. Aydin, H. D. Demir, and S. Sahin, "Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy," *Current Eye Research*, vol. 35, pp. 230–234, 2010.
- [32] G. Ferrari-Dileo, J. W. Ryan, and E. J. Rockwood, "Angiotensin-converting enzyme in bovine, feline, and human ocular tissues," *Investigative Ophthalmology & Visual Science*, vol. 29, pp. 876–881, 1988.
- [33] R. Igić and V. Kojović, "Angiotensin I converting enzyme (kininase II) in ocular tissues," *Experimental Eye Research*, vol. 30, pp. 299–303, 1980.
- [34] I. Immonen, K. Friberg, and R. Sorsila, "Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis," *Acta Ophthalmologica*, vol. 65, pp. 27–29, 1987.
- [35] M. Ramirez, E. A. Davidson, and L. Luttenauer, "The renin-angiotensin system in the rabbit eye," *Journal of Ocular Pharmacology and Therapeutics*, vol. 12, pp. 299–312, 1996.
- [36] Y. Sun, L. Liu, and X. Pan, "Mechanism of the action between the SARS-CoV S240 protein and the ACE2 receptor in eyes," *International Journal of Ophthalmology*, vol. 6, pp. 783–786, 2006.
- [37] M. Sotoyama, M. B. G. Villanueva, and H. Jonai, "Ocular surface area as an informative index of visual ergonomics," *Industrial Health*, vol. 33, no. 2, pp. 43–55, 1995.
- [38] M. Zaman, M. Doughty, and N. Button, "The exposed ocular surface and its relationship to spontaneous eyeblink rate in elderly caucasians," *Experimental Eye Research*, vol. 67, no. 6, pp. 681–686, 1998.
- [39] M. T. Coroneo, "The eye as the discrete but defensible portal of coronavirus infection," *The Ocular Surface*, vol. S1542-0124, no. 1520, 2020.
- [40] F. Paulsen, "The human nasolacrimal ducts," *Advances in Anatomy Embryology and Cell Biology*, vol. 170, 2003.
- [41] K. Y. Seo, S. J. Han, and H. R. Cha, "Eye mucosa: an efficient vaccine delivery route for inducing protective immunity," *Journal Immunology*, vol. 185, no. 6, pp. 3610–3619, 2010.
- [42] P. E. Napoli, M. Nioi, and E. D'Aloja, "The ocular surface and the coronavirus disease 2019: does a dual 'ocular route' exist?," *Journal of Clinical Medicine*, vol. 9, p. 1269, 2020.
- [43] L. Liang and P. Wu, "There may be virus in conjunctival secretion of patients with COVID-19," *Acta Ophthalmologica*, vol. 98, pp. 223–223, 2020.
- [44] Z. Liu and C.-B. Sun, "Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract," *Journal of Medical Virology*, vol. 92, no. 9, pp. 1410–1412, 2020.
- [45] H. Qing, Z. Li, and Z. Yang, "The possibility of COVID-19 transmission from eye to nose," *Acta Ophthalmologica*, vol. 98, 2020.
- [46] S. Bunyavanich, A. Do, and A. Vicencio, "Nasal gene expression of angiotensin-converting enzyme 2 in children and adults," *JAMA*, vol. 323, p. 2427, 2020.
- [47] L. Liu, Y. Sun, and X. Pan, "Expression of SARS coronavirus S protein functional receptor - angiotensin-converting enzyme 2 in human cornea and conjunctiva," *Chin Ophthalmic Research*, vol. 22, pp. 561–564, 2004.
- [48] W. Deng, L. Bao, and H. Gao, *Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques*, Cold Spring Harbor Laboratory, 2020.
- [49] K. P. Y. Hui, M.-C. Cheung, and R. A. P. M. Perera, "Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures," *The Lancet Respiratory Medicine*, vol. 8, no. 7, pp. 687–695, 2020.
- [50] M. Olbei, I. Hautefort, and D. Modos, "SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients," *Frontiers in Immunology*, vol. 12, 2021.



- [51] M. Dilauro and K. D. Burns, "Angiotensin-(1-7) and its effects in the kidney," *The Scientific World Journal*, vol. 9, 535 pages, 2009.
- [52] A. Verma, Z. Shan, B. Lei et al., "ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy," *Molecular Therapy*, vol. 20, no. 1, pp. 28–36, 2012.
- [53] R. A. Santos, A. J. Ferreira, and T. Verano-Braga, "Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system," *Journal Endocrinology*, vol. 216, 2013.
- [54] K. Kuba, Y. Imai, S. Rao et al., "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury," *Nature Medicine*, vol. 11, pp. 875–879, 2005.
- [55] K. Kuba, Y. Imai, and S. Rao, "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury," *Nature Medicine*, vol. 11, pp. 875–879, 2005.
- [56] J. Chen, Q. Jiang, and X. Xia, "Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation," *Aging Cell*, vol. 19, article e13168, 2020.
- [57] M. C. Gagliardi, P. Tieri, and E. Ortona, "ACE2 expression and sex disparity in COVID-19," *Cell Death Discovery*, vol. 6, no. 1, p. 37, 2020.
- [58] M. Hoffmann, H. Kleine-Weber, and S. Schroeder, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor," *Cell*, vol. 181, pp. 271–280.e278, 2020.
- [59] D. Pan, S. Sze, and J. S. Minhas, "The impact of ethnicity on clinical outcomes in COVID-19: a systematic review," *EclinicalMedicine*, vol. 23, pp. 100404–100404, 2020.
- [60] Y. Zhao, Z. Zhao, and Y. Wang, *Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2*, Cold Spring Harbor Laboratory, 2020.
- [61] Office for National Statistics, *Coronavirus (COVID-19) related deaths by ethnic group*, England and Wales, 2020 <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/coronaviruscovid19relateddeathsbyethnicgroupenglandandwales/2march2020to15may2020>.
- [62] Q. Li, Z. Cao, and P. Rahman, "Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations," *Molecular Genetics & Genomic Medicine*, vol. 8, article e1344, 2020.
- [63] A. Zumla, J. F. W. Chan, and E. I. Azhar, "Coronaviruses-drug discovery and therapeutic options," *Nature Reviews Drug Discovery*, vol. 15, pp. 327–347, 2016.
- [64] C. G. Brilla, "Renin-angiotensin-aldosterone system and myocardial fibrosis," *Cardiovascular Research*, vol. 47, pp. 1–3, 2000.
- [65] K. Y. Shim, Y. W. Eom, M. Y. Kim, S. H. Kang, and S. K. Baik, "Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension," *The Korean Journal of Internal Medicine*, vol. 33, pp. 453–461, 2018.
- [66] J. Wang, L. Chen, B. Chen et al., "Chronic activation of the renin-angiotensin system induces lung fibrosis," *Scientific Reports*, vol. 5, pp. 15561–15561, 2015.
- [67] World Health Organisation, *COVID-19 vaccines*, 2020, <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines>.
- [68] World Health Organisation, *Draft landscape and tracker of COVID-19 candidate vaccines*, 2021, <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>.
- [69] F. P. Polack, S. J. Thomas, and N. Kitchin, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine," *New England Journal of Medicine*, vol. 383, no. 27, pp. 2603–2615, 2020.
- [70] Pfizer, *COVID-19 Vaccine U.S.*, 2020, distribution fact sheet, [https://www.pfizer.com/news/hot-topics/covid\\_19\\_vaccine\\_u\\_s\\_distribution\\_fact\\_sheet](https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet).
- [71] Centers for Disease Control and Prevention, *Moderna COVID-19 vaccine questions*, 2021, <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/moderna-faqs.html>.
- [72] L. R. Baden, H. M. El Sahly, B. Essink et al., "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine," *New England Journal of Medicine*, vol. 384, 2021.
- [73] M. Voysey, S. A. C. Clemens, and S. A. Madhi, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK," *The Lancet*, vol. 397, pp. 99–111, 2021.
- [74] M. D. Knoll and C. Wonodi, "Oxford–AstraZeneca COVID-19 vaccine efficacy," *The Lancet*, vol. 397, pp. 72–74, 2021.
- [75] World Health Organisation, *COVAX announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021*, 2020, <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>.
- [76] G. J. Milne and S. Xie, *The effectiveness of social distancing in mitigating COVID-19 spread: a modelling analysis*, Cold Spring Harbor Laboratory, 2020.